Phase 2 Retinal Disease Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting
Phase 2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Phase 2
SGLT2 Inhibitors in Geographic Atrophy
Geographic AtrophyRetinal diseasesRetinal Degeneration+2 more
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Phase 1Phase 2
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 1Phase 2
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting
Phase 1Phase 2
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Recruiting
Phase 1Phase 2
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.20 enrolled3 locationsNCT05906953